• FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96


innoVitro - Statement about FLEXcyte technology

Icon FLEX  “We have been working with Nanion for several years on technology development projects and joint commercialization. Nanion is a prime example of an agile approach and customer orientation.”

Dr. Matthias Gossmann
co-founder and CEO at innoVitro, Germany. (CRO, FLEXcyte Service Provider)

Icon FLEX  “Human iPSC-derived cardiomyocytes are the future of safe and efficient drug development. The FLEXcyte technology provides a tool for functional cardiac toxicology and efficacy screening on these cells. Force-frequency relation are the subject of current scientific discussions and require an assay technology that can accurately quantify them and we meet this need with the FLEXcyte 96.

Dr. Peter Linder
CTO innoVitro, Germany. (CRO, FLEXcyte Service Provider)

FLEXcyte 96 Brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.